MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria
Trial Timeline
Apr 18, 2024 → Jan 6, 2025
NCT ID
NCT06294912About MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanil is a phase 1 stage product being developed by Merck for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT06294912. Target conditions include Malaria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06294912 | Phase 1 | Completed |
Competing Products
20 competing products in Malaria